专业文献
可载药微球tace对比传统tace治疗不可切除肝细胞癌患者的评估:系统性回顾和meta分析-ag捕鱼平台
evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
可载药微球tace对比传统tace治疗不可切除肝细胞癌患者的评估:系统性回顾和meta分析
方法:在pubmed、embase、中国生物医学文献数据库(cbm)、cochrane图书馆数据库这四个电子数据库中系统性检索自2015年12月25日至今的包含“hcc”和“drug-eluting beads”这两个关键词的临床研究。运用review manager 5.3软件计算综合相对危险度(rrs)和95%置信区间(cis)。
results: sixteen cohort studies (4 rcts, 3 prospective cohorts, 9 retrospective cohorts) were included comprising a total of 1832 patients: 822 patients with deb-tace therapy and 1010 patients undergoing ctace. the 1-, 2-, and 3-year overall survival (os) rates and 1- and 2-year relapse-free survival(rfs) rates were significantly higher in deb-tace group, with pooled rrs of 1.12 (95% ci = 1.03-1.23, p = 0.007), 1.26 (95% ci = 1.03-1.54, p = 0.02), 1.69 (95% ci = 1.00-2.84, p = 0.04), 1.21 (95% ci = 1.01-1.44, p = 0.03) and 1.68(95% ci = 1.17-2.43, p = 0.005). there was no statistical significance in 3-year rfs, tumor response and treatment related adverse events.
conclusions: this meta-analysis indicates the potential advantage of deb-tace in improving the 1-, 2- and 3-year os rates, and the 1- and 2-year rfs rates.
结论:相较ctace治疗,deb-tace治疗能显著提高患者1年、2年和3年总生存率及1年、2年无复发生存率。